In this regard, our findings suggested that targeting of DYRK1A may serve as a novel approach to reduce Mcl-1 protein stability in NSCLC cells and thereby prevent Bcl-2 inhibitor resistance. This evidence concerns the gene BCL2 and non-small cell lung carcinoma.